Buys | $82,990 | 3 | 13 |
Sells | $10,368,351 | 21 | 87 |
Lu Hongbo | director | 3 | $82,990 | 0 | $0 | $82,990 |
OLUKOTUN ADEOYE Y | director | 0 | $0 | 2 | $77,139 | $-77,139 |
GIVEN DOUGLAS B | director | 0 | $0 | 2 | $121,556 | $-121,556 |
Waddill William D. | director | 0 | $0 | 2 | $164,665 | $-164,665 |
Oliver Tracie | Chief Commercial Officer | 0 | $0 | 1 | $237,480 | $-237,480 |
Vakiener Victoria | director | 0 | $0 | 2 | $238,993 | $-238,993 |
O'Brien Patrick | COO and General Counsel | 0 | $0 | 2 | $736,059 | $-736,059 |
Hamilton James C | Chief Discovery/Trans Medicine | 0 | $0 | 2 | $817,004 | $-817,004 |
Myszkowski Kenneth Allen | Chief Financial Officer | 0 | $0 | 2 | $893,095 | $-893,095 |
Anzalone Christopher Richard | Chief Executive Officer | 0 | $0 | 6 | $7.08M | $-7.08M |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in …
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $10.37M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $52,573 and sold $21.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $82,990.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
2025-03-13 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 51,425 0.0374% | $15.07 | $774,975 | +1.92% | |
2025-03-04 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 133,333 0.104% | $17.02 | $2.27M | -9.53% | |
2025-03-03 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 166,667 0.1344% | $18.03 | $3.01M | -11.91% | |
2025-01-23 | Sale | OLUKOTUN ADEOYE Y | director | 959 0.0007% | $21.00 | $20,139 | -11.24% | |
2025-01-07 | Sale | O'Brien Patrick | COO and General Counsel | 8,000 0.0065% | $19.69 | $157,520 | -2.85% | |
2025-01-07 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 18,000 0.0146% | $19.69 | $354,500 | -2.85% | |
2025-01-06 | Sale | O'Brien Patrick | COO and General Counsel | 29,184 0.0236% | $19.82 | $578,539 | -0.92% | |
2025-01-06 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 27,167 0.022% | $19.83 | $538,595 | -0.92% | |
2025-01-06 | Sale | Hamilton James C | Chief Discovery/Trans Medicine | 32,729 0.0265% | $19.82 | $648,824 | -0.92% | |
2025-01-02 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 11,520 0.009% | $19.05 | $219,456 | -0.69% | |
2024-12-27 | Sale | OLUKOTUN ADEOYE Y | director | 2,850 0.0024% | $20.00 | $57,000 | +2.85% | |
2024-12-23 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 12,563 0.0099% | $19.59 | $246,109 | -1.19% | |
2024-12-18 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 26,712 0.0226% | $21.24 | $567,486 | -4.22% | |
2024-12-17 | Sale | GIVEN DOUGLAS B | director | 547 0.0004% | $22.04 | $12,056 | -12.37% | |
2024-12-17 | Sale | Waddill William D. | director | 3,747 0.003% | $22.04 | $82,584 | -12.37% | |
2024-12-16 | Sale | GIVEN DOUGLAS B | director | 5,000 0.004% | $21.90 | $109,500 | -12.70% | |
2024-12-16 | Sale | Waddill William D. | director | 3,748 0.003% | $21.90 | $82,081 | -12.70% | |
2024-12-16 | Sale | Vakiener Victoria | director | 8,994 0.0071% | $21.91 | $197,059 | -12.70% | |
2024-07-02 | Sale | Oliver Tracie | Chief Commercial Officer | 9,394 0.0073% | $25.28 | $237,480 | -19.19% | |
2024-05-02 | Sale | Vakiener Victoria | director | 1,799 0.0014% | $23.31 | $41,935 | -11.15% |
Anzalone Christopher Richard | Chief Executive Officer | 4062377 2.9584% | $61.32M | 4 | 41 | <0.0001% |
Myszkowski Kenneth Allen | Chief Financial Officer | 455433 0.3317% | $6.87M | 1 | 29 | <0.0001% |
GIVEN DOUGLAS B | director | 124167 0.0904% | $1.87M | 1 | 21 | <0.0001% |
Lu Hongbo | director | 33680 0.0245% | $508,399.60 | 3 | 0 | |
KNOTT DAVID M | 10 percent owner | 166778 0.1215% | $2.52M | 1 | 3 | <0.0001% |
$66,492,695 | 135 | 27.65% | $2.05B | |
$1,376,668 | 53 | 18.46% | $2.31B | |
$11,583,737 | 45 | 49.75% | $1.76B | |
$224,267,561 | 40 | 26.78% | $2.17B | |
$148,770,544 | 34 | 80.63% | $1.74B |
Increased Positions | 137 | +43.63% | 10M | +10.01% |
Decreased Positions | 131 | -41.72% | 8M | -7.87% |
New Positions | 45 | New | 2M | New |
Sold Out Positions | 44 | Sold Out | 2M | Sold Out |
Total Postitions | 320 | +1.91% | 101M | +2.14% |
Blackrock, Inc. | $248,494.00 | 11.81% | 16.18M | +342,088 | +2.16% | 2024-12-31 |
Vanguard Group Inc | $187,151.00 | 8.89% | 12.18M | -44,766 | -0.37% | 2024-12-31 |
Avoro Capital Advisors Llc | $170,667.00 | 8.11% | 11.11M | +2M | +25% | 2024-12-31 |
State Street Corp | $92,409.00 | 4.39% | 6.02M | -338,104 | -5.32% | 2024-12-31 |
Slate Path Capital Lp | $80,364.00 | 3.82% | 5.23M | +347,000 | +7.1% | 2024-12-31 |
Fmr Llc | $78,353.00 | 3.72% | 5.1M | -966,486 | -15.93% | 2024-12-31 |
Geode Capital Management, Llc | $45,388.00 | 2.16% | 2.95M | -9,172 | -0.31% | 2024-12-31 |
Siren, L.L.C. | $44,570.00 | 2.12% | 2.9M | +442,903 | +18.01% | 2024-12-31 |
T. Rowe Price Investment Management, Inc. | $38,512.00 | 1.83% | 2.51M | -1M | -29.86% | 2024-12-31 |
Norges Bank | $31,555.00 | 1.5% | 2.05M | +469,044 | +29.59% | 2024-12-31 |